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Epoxide electrophiles as activity-dependent cysteine protease
pro¢ling and discovery tools
Doron Greenbaum 1, Katalin F Medzihradszky 1;2, Alma Burlingame 1;2 and
Matthew Bogyo 3
Background: Analysis of global changes in gene transcription and translation by
systems-based genomics and proteomics approaches provides only indirect
information about protein function. In many cases, enzymatic activity fails to
correlate with transcription or translation levels. Therefore, a direct method for
broadly determining activities of an entire class of enzymes on a genome-wide
scale would be of great utility.
Results: We have engineered chemical probes that can be used to broadly track
activity of cysteine proteases. The structure of the general cysteine protease
inhibitor E-64 was used as a scaffold. Analogs were synthesized by varying the
core peptide recognition portion while adding af¢nity tags (biotin and radio-iodine)
at distal sites. The resulting probes containing a P2 leucine residue (DCG-03 and
DCG-04) targeted the same broad set of cysteine proteases as E-64 and were
used to pro¢le these proteases during the progression of a normal skin cell to a
carcinoma. A library of DCG-04 derivatives was constructed in which the leucine
residue was replaced with all natural amino acids. This library was used to obtain
inhibitor activity pro¢les for multiple protease targets in crude cellular extracts.
Finally, the af¢nity tag of DCG-04 allowed puri¢cation of modi¢ed proteases and
identi¢cation by mass spectrometry.
Conclusions: We have created a simple and £exible method for functionally
identifying cysteine proteases while simultaneously tracking their relative activity
levels in crude protein mixtures. These probes were used to determine relative
activities of multiple proteases throughout a de¢ned model system for cancer
progression. Furthermore, information obtained from libraries of af¢nity probes
provides a rapid method for obtaining detailed functional information without the
need for prior puri¢cation/identi¢cation of targets.
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Introduction
New approaches for studying global cellular processes
must permit the analysis of differential changes within
large sets of known and unknown genes or proteins.
DNA microarray techniques allow analysis of genome-
wide changes in mRNA transcription for a given cellular
stimulus [1,2]. Advances in two-dimensional (2D) gel elec-
trophoresis coupled to highly sensitive mass spectrometry
techniques now allow the rapid identi¢cation of proteins
from whole cells or tissue extracts [3,4]. While these tech-
niques have revolutionized the global analysis of biological
processes, often information about function of enzymatic
proteins can only be inferred by analysis of transcriptional/
translational co-regulation of sets of genes under different
stimuli. In fact, levels of transcription and translation of an
enzyme, in many cases, do not correlate with its activity
[5].
To assign a function to enzymatic proteins on a genome-
wide scale, a method to obtain direct information about
enzymatic activity is necessary. Since the simultaneous tar-
geting of all enzyme classes with a single probe is likely to
be impossible, we chose to focus our effort on proteolytic
enzymes. The papain family of cysteine proteases serves as
a good model system for several reasons. Firstly, most cys-
teine proteases are synthesized with an inhibitory propep-
tide that must be proteolytically removed to activate the
enzyme [6,7], resulting in expression pro¢les that do not
directly correlate with activity. Secondly, the largest set of
papain-like cysteine proteases, the cathepsins, act in con-
cert to digest a protein substrate. Thus, information regard-
ing regulation of activity of each member relative to one
another is critical for understanding their collective func-
tion. Furthermore, the cathepsins are involved in many
critical biological processes, and biochemical studies of
function have been limited to family members that have
been cloned and expressed or puri¢ed from crude tissue.
Finally, a large body of information is available regarding
covalent, mechanism-based inhibitors that speci¢cally tar-
get this family of cysteine proteases.
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The papain family is classi¢ed into several major groups,
most notable of which are the bleomycin hydrolases, cal-
pains, caspases and cathepsins. To date, 16 human cathep-
sins have been cloned and sequenced. Several of these
proteases are key players in normal physiological processes
such as antigen presentation [8], bone remodeling [9] and
prohormone processing [10]. In addition, several of these
proteases are involved in pathological processes such as
rheumatoid arthritis [11], cancer invasion and metastasis
[12] and Alzheimer’s disease [13,14].
The enzymatic mechanism used by the papain family of
proteases has been well studied and is highly conserved.
Thus, electrophilic substrate analogs that are only reactive
in the context of this conserved active site can be used as
general probes of function. A wide range of electrophiles
has been developed as mechanism-based, cysteine pro-
tease inhibitors including diazomethyl ketones [15], £uo-
romethyl ketones [16], acyloxymethyl ketones [17], O-acyl-
hydroxylamines [18], vinyl sulfones [19] and epoxysuccinic
derivatives [20]. These inhibitors all consist of a peptide
speci¢city determinant attached to an electrophile that be-
comes irreversibly alkylated when bound in close proxim-
ity to an attacking nucleophile.
Several groups have recognized the value of using irrevers-
ible mechanism-based inhibitors as af¢nity labels [21^25].
Addition of a reporter function, such as a radioactive io-
dine, to inhibitors permits the visualization of covalently
modi¢ed proteases in a standard SDS^PAGE gel format.
Labeling intensity provides a read-out of relative enzy-
matic activity. Furthermore, both known and novel pro-
teases are targets for analysis by this methodology. Similar
af¢nity labeling approaches have been used extensively to
study or identify proteases such as the proteasome
[22,26,27], caspases [28,29], cathepsins [23,25] and methio-
nine amino peptidase [30,31]. Recently, Cravatt and co-
workers have taken advantage of the broad class-speci¢c
reactivity of £uorophosphonates towards serine proteases
[32]. By incorporation of a simple, extended alkyl chain
capped with a biotin moiety, they have created a broad
serine protease-speci¢c probe (FP-Biotin) for functional
proteomic analysis of serine proteases in crude cellular ex-
tracts.
We have developed functional proteomics tools that can be
used to determine global patterns of activity for the papain
family of cysteine proteases based on the broad reactivity
of the natural product E-64. These tools provide functional
information that can be used in concert with existing ge-
Figure 1. Structures of epoxide inhibitors and probes E-64, JPM-565, DCG-03 and DCG-04. Radiolabel attachment and af¢nity sites are
indicated for each compound.
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nomic and proteomic methods to correlate gene and pro-
tein expression pro¢les with enzymatic activity. Further-
more, diversi¢cation of core compounds using solid-phase
combinatorial chemistry provides libraries of compounds
that can be used to obtain information about inhibitor spe-
ci¢cities of targeted protease. This information is likely to
be of use in the generation of selective inhibitors without
the need for prior characterization and puri¢cation of pro-
tease targets. Finally, the probes themselves can be used to
rapidly identify targets after covalent modi¢cation.
Results and discussion
Design and synthesis of DCG-04
The natural product E-64 is a promiscuous irreversible
cysteine protease inhibitor that is broadly reactive toward
the papain family of cysteine proteases [20] (Figure 1). Its
leucine side chain mimics the P2 amino acid of a substrate,
occupying the target’s S2 binding pocket while the agma-
tine moiety binds in the S3 position [33]. Rich et al. syn-
thesized JPM-565 (Figure 1), a derivative in which a tyr-
amine moiety replaces the agmatine side chain of E-64
[34,35]. This closely related compound was found to
have similar class-speci¢c reactivity for cysteine proteases
as E-64. Since the P2 position of a substrate is considered
to be the main speci¢city determinant for many cysteine
proteases, we reasoned that further extension of the non-
prime binding portion of JPM-565 would not signi¢cantly
perturb binding af¢nity for a target protease. In addition,
modi¢cation to the non-prime site binding element of the
E-64 derivative CA-074 had little effect on binding to ca-
thepsin B [23,36]. Elaboration of the peptide portion of E-
64 allowed both incorporation of an af¢nity tag as well as
attachment of the compound to a solid support. The re-
sulting bi-functional compounds, DCG-03 and DCG-04,
contain both the iodinatable phenol ring of JPM-565 and
the additional af¢nity site created by incorporation of a
side chain biotinylated lysine residue (Figure 1). Addition
(DCG-04) or removal (DCG-03) of an amino hexanoic acid
spacer between the af¢nity site and the electrophile was
used to determine the space requirement for binding and
recognition of the af¢nity label by support-bound avidin.
Peptide epoxides were synthesized using a combination of
solution and solid-phase chemistries. The solution-phase
synthesis of the epoxide acid building block (Figure 2A)
starting from commercially available diethyl tartrate has
been reported elsewhere [23]. Standard solid-phase pep-
tide chemistry was used to build the peptide portion of
DCG-04 and related compounds (Figure 2B). This meth-
odology provides a £exible system with which to incorpo-
rate virtually any peptide sequence prior to attachment of
the electrophilic epoxide. Surprisingly, the epoxy acid
building block was stable to standard solid-phase peptide
synthesis cleavage conditions (95% TFA). The use of sol-
id-phase chemistry also allowed the synthesis of a diverse
library in which the P2 leucine of DCG-04 was replaced
with each of the natural amino acids (except cysteine due
to reactivity with the epoxide and methionine due to ox-
idation). The non-natural amino acid norleucine was used
as an isosteric methionine analog. The results obtained
using this 19 member library of compounds are described
below.
DCG-04 is an activity-dependent af¢nity label
Dendritic cells express relatively high levels of lysosomal
cathepsins, making them a logical source of material for
Figure 2. Synthesis of DCG-04. (A) Epoxy
acid building block (I) and (B) solid-phase
synthesis scheme for DCG-04. Details of
the synthesis and characterization of
peptide epoxides can be found in Materials
and methods.
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establishing parameters for the use of DCG-04. Figure 3
shows the labeling pro¢le of polypeptides modi¢ed by in-
cubation with either DCG-03, DCG-04, 125I-DCG-03 or
125I-DCG-04 followed by SDS^PAGE analysis. Radio-iodi-
nated (autoradiogram) and non-radio-iodinated (blot)
DCG-03 and DCG-04 labeled multiple polypeptides in
the range of 20^40 kDa.
Although the intrinsic reactivity of the epoxide electrophile
portion of DCG-04 towards free thiols is quite poor, we
wanted to determine if DCG-04 and its derivatives were
capable of non-speci¢c alkylation of proteins in crude cel-
lular extracts. A pre-heating control was used to reveal non-
speci¢c labeling, with the assumption that denatured, in-
active proteins modi¢ed by DCG-03 and DCG-04 repre-
sent non-speci¢c modi¢cations. Enzymatically active pro-
teins were deduced by subtraction (Figure 3). Labeling of
all of the major species in the 20^40 kDa size range was
lost upon heat denaturation of samples prior to addition of
compounds, suggesting that labeling is dependent on en-
zymatic activity and that these bands correspond to the
major proteases in the extract. Several higher molecular
weight species were observed by af¢nity blotting of both
denaturing controls and samples in which no inhibitor was
added. These species are likely to represent non-speci¢c
alkylations and endogenously biotinylated proteins.
Comparison of labeling, at neutral (pH 7.4) and at the
acidic pH of the lysosome (pH 5.5), indicated that several
of the modi¢ed polypeptides in the 30 kDa size range
required reduced pH for activity. This result is consistent
with reported ¢ndings that several lysosomal cysteine pro-
teases either reversibly or irreversibly lose activity upon
de-acidi¢cation of lysosomal compartments [37].
Analysis of the labeling of DC2.4 lysates by both af¢nity
blot and autoradiography techniques resulted in similar
pro¢les of modi¢ed polypeptides, highlighting the utility
of both techniques. However, the autoradiogram showed
labeling of only enzymatically active polypeptides by radio-
labeled forms of DCG-03 and DCG-04. Addition of the
rather bulky iodine atom to DCG-03 and DCG-04 had
only a modest effect on target modi¢cation yet resulted
in compounds with dramatically reduced background label-
ing and increased sensitivity. Ultimately, the ability to use
both autoradiography as well as blot techniques enhances
the £exibility of these protease detection reagents and fur-
ther highlights the utility of bi-functional inhibitors.
DCG-04 targets cysteine proteases inhibited by E-64 and
JPM-565
Both direct labeling and indirect competition experiments
were performed to con¢rm that DCG-04 reacts with a sim-
Figure 3. DCG-03 and DCG-04 label active proteases in dendritic cell extracts. (A) Total cell extracts from DC2.4 cells were diluted into
either pH 5.5 or pH 7.4 buffer, pre-heated to 100³C for 1 min (+pre-heating) or not (3pre-heating) and labeled with 50 WM DCG-03 and
DCG-04. Samples were separated by SDS^PAGE (12.5% gel) and labeled bands visualized by af¢nity blotting as described in Materials
and methods. (B) Same as for (A) except 125I-labeled versions of DCG-03 and DCG-04 were used and gels analyzed by autoradiography.
The locations of cathepsins B, L and S are indicated for reference based on their known molecular weights.
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ilar subset of proteases to the parent compounds E-64 and
JPM-565. An indirect competition experiment was re-
quired to determine the polypeptides modi¢ed by E-64
since it lacks an af¢nity labeling site. Extracts from the
dendritic cell line DC2.4 were preincubated with an in-
creasing concentration of E-64 followed by labeling with
DCG-04. Final labeling intensity was used to indirectly
monitor the extent of polypeptide modi¢cation by E-64.
The competition revealed that all polypeptides labeled by
DCG-04 are effectively competed by E-64, indicating that
the two compounds target the same subset of proteases
(Figure 4A). A similar competition experiment was per-
formed using the cathepsin B-speci¢c inhibitor MB-074
[23]. These results positively identi¢ed the diffuse 30
kDa polypeptide (labeled cat B in Figure 4A) as cathepsin
B (data not shown).
Comparison of the speci¢city of DCG-03, DCG-04 and
JPM-565 was accomplished using direct labeling of
DC2.4 cell lysates. Labeling pro¢les obtained for 125I-
DCG-03, 125I-DCG-04 and 125I-JPM-565 were identical
for all three probes and indicated that each targeted poly-
peptides in the 20^40 kDa size range (Figure 4B). Analysis
of non-radiolabeled DCG-03-, DCG-04- and JPM-565-
treated extracts again showed the similarity of the blotting
and autoradiography detection systems. As expected, JPM-
565, which lacks a biotin label, showed no labeling as
detected by af¢nity blotting. Together these results estab-
lish that modi¢cations to the extended binding portion of
the E-64 family of compounds have little effect on selec-
tivity or potency. However, this region of the inhibitor may
still play an important role in establishing speci¢city of
binding when equipped with the proper recognition se-
quence. Future work is aimed at exploring the use of ex-
tended peptide recognition motifs to ¢ne tune selectivity
of the DCG family of inhibitors for speci¢c protease tar-
gets.
Pro¢ling applications
The aforementioned methods established the initial pa-
rameters for use of the general cysteine protease labels
DCG-03 and DCG-04. We next wanted to apply these
techniques to pro¢le the activity and speci¢city of cysteine
proteases in several different model systems. The broadly
reactive probe DCG-04 was used to generate activity pro-
¢les of multiple protease targets both in a model for dis-
ease progression and throughout multiple tissue types.
Similarly, activity pro¢les were generated using the cathep-
sin B-speci¢c probe MB-074 to provide complementary
information for a single, well-de¢ned cysteine protease tar-
get. This information was also used to positively establish
the identity of cathepsin B in the DCG-04 labeling pro-
Figure 4. DCG-03 and DCG-04 target the same polypeptides as parent compounds E-64 and JPM-565. (A) Total cellular extracts from
DC2.4 cells were incubated with increasing concentrations of E-64 as indicated for 30 min at 25³C followed by addition of 50 WM DCG-04
and further incubation for 1 h. Samples were resolved by SDS^PAGE (12.5%) and labeled bands visualized by af¢nity blotting. (B) Total
cellular extracts were labeled with either 125I-labeled forms (auto-rad) or with non-labeled forms (blot) of DCG-03, DCG-04 and JPM-565
followed by separation by SDS^PAGE (12.5%) and analysis as indicated. The locations of cathepsin B and S are indicated for reference
based on their known molecular weights.
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¢les. To obtain more detailed functional information for
DCG-04-modi¢ed proteases, inhibitor speci¢city pro¢les
were generated using a library of DCG-04 analogs in total
cellular extracts. The same libraries were also used in con-
junction with the cathepsin B-speci¢c probe, 125I-MB-074,
as well as with puri¢ed cathepsin H to determine speci¢c-
ity pro¢les for individual target proteases. These results are
described below.
Pro¢ling across disease progression using DCG-04 and MB-074
The mouse skin model of multi-stage carcinogenesis has
been well studied genotypically and phenotypically, has
discrete steps in the progression, but lacks information
on cysteine protease involvement [38,39]. The role of ca-
thepsins in tumor biology has mostly focused on cathepsins
B and L. Upregulated levels of both cathepsins B and L
have been shown to correlate with an invasive phenotype
[12,40]. Furthermore, cathepsins B and L are secreted by
many types of tumorigenic cells and treatment of invasive
cells with the cysteine protease inhibitor E-64 results in a
block in cellular invasion into a synthetic matrix [41,42].
These data indicate that cathepsins are likely to play an
important role in the metastatic process.
Ten cell lines representing various steps in the progression
from benign skin cell (C5N) to highly invasive spindle cell
carcinomas (Car B and Car C) were used to analyze global
changes in activity of cathepsins throughout this multi-
stage carcinogenesis model. The carcinoma progression
also includes benign papilloma cell lines P6, PDV and
PDV-C57, and more invasive squamous cell carcinoma
cell lines B9, A5 and D3. Equal amounts of protein from
each cell lysate were labeled with both the broadly reactive
probe, 125I-DCG-04, as well as the cathepsin B-speci¢c
probe, 125I-MB-074 at pH 5.5 (Figure 5). The results
show that several protease activities, including cathepsin
B, dramatically £uctuate across the panel of cell lines.
The broadly reactive probe 125I-DCG-04 highlights the
activity of several proteases in the lysosomal cysteine pro-
tease size range in each of the cell types (Figure 5A). The
benign cell lines C5N and P6 both contain multiple la-
beled polypeptides between 28 and 45 kDa; however,
the labeling intensity observed for the P6 line is dramati-
cally increased for all polypeptides in this range. Interest-
ingly, the major difference between these cell lines is an
activating mutation in the ras gene [43]. It has previously
been shown that various classes of proteases, including the
cathepsins, are upregulated downstream of Ras; however,
these studies were limited to analysis of expression levels
of cathepsin B and H [44].
Figure 5. Activity pro¢ling across a disease progression. Tissue culture cells were isolated from carcinomas generated by application of a
chemical mutagen to the skin of mice (see Materials and methods). Progression begins at the left with the non-invasive benign cells (C5N
and P6) and progresses to the right through papilloma cell lines (PDV and PDV-C57), squamous cell carcinomas (B9, A5 and D3) and
¢nally highly invasive spindle cell carcinomas (Car B and Car C). Total cellular lysates were normalized with respect to protein
concentration and labeled with (A) 125I-DCG-04 and (B) the cathepsin B-speci¢c probe 125I-MB-074. A pre-heat control from the C5N lysate
was included in (A) to show background labeling.
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The papilloma cell lines PDV and PDV-C57 show nearly
identical patterns of labeling (Figure 5A). However, these
pro¢les are dramatically different than the pro¢le observed
for C5N and P6 lysates. A predominant 30 kDa polypep-
tide (cathepsin B; see below) is labeled along with a less
intensely labeled 21 kDa polypeptide. The squamous cell
carcinoma cell lines B9, A5 and D3 result in similar pro¢les
of modi¢ed polypeptides. While all three lines are nearly
identical cancer cell types, only B9 shows appreciable la-
beling of the major 30 kDa and 21 kDa polypeptides.
Similarly, the two highly invasive spindle cell carcinomas
Car B and Car C show similar, but not identical, labeling
pro¢les. The 21 kDa species, in particular, shows differ-
ential labeling in the two cell types. These ¢ndings illus-
trate that cells isolated from different tumor sources have
different protease activities. This signature of protease ac-
tivity may in fact be unique to each cell and/or tumor,
much the same way genomics studies by Browne and col-
leagues have shown that individual tumor cells have
unique global gene expression pro¢les [45].
The cathepsin B-speci¢c label 125I-MB-074 was used to
directly examine the pro¢le of cathepsin B activity in the
same collection of cells described (Figure 5B). This probe
has been found to label cathepsin B in a highly speci¢c
manner [23]. Labeling of cathepsin B dramatically changed
across the pro¢le of cell types with the greatest activity
observed for the PDV and PDV-C57 lines. Furthermore,
the apparent molecular weight, as well as the sharpness of
the cathepsin B, band differed for the benign and spindle
cell carcinomas, suggesting that this enzyme is modi¢ed
differently in these cell types. This change in migration
for cathepsin B may be due to changes in glycosylation or
other post-translational modi¢cations. Cathepsin B has
been found to exist as different isoforms with differing
pIs in various tumor cells as a result of changes in glyco-
sylation and traf¢cking [46]. Changes in the post-transla-
tional modi¢cation of cathepsin B are likely to affect the
localization of active forms of the enzyme and therefore
may play an important role in the control of cathepsin B
activity in tumors [46]. Overall, the results obtained from
labeling with 125I-MB-074 further highlight the variability
Figure 6. Pro¢ling protease inhibitor speci¢city. Lysates from the dendritic cell line DC2.4 (A,B) or puri¢ed cathepsin H (C) were
preincubated with 50 WM of each of the 19 derivatives of DCG-04 and then labeled with 125I-DCG-04 (A,C) or 125I-MB-074 (B) as
indicated. The general structures of the inhibitors are shown with the variable amino acid side chain indicated as an X (competitor; top).
The predominant labeled polypeptides in (A) are labeled with numbers, and positions of cathepsins B and S are indicated for reference.
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of cathepsin B activity found in different types of tumor
cells as well as in nearly identical cell lines derived from
different sources.
Pro¢ling protease speci¢city using a library of inhibitors
To take advantage of the £exibility and ease of synthesis
of the DCG-04 family of compounds, we created a small
library of compounds in which the peptide recognition
portion of the molecule is modi¢ed. It has been proposed
that the main speci¢city regions within the active binding
site of the cathepsins are S2, S1, S1P and S2P, with S2
containing the main binding pocket [47]. Since the leucine
residue of E-64 binds in the critical S2 pocket of many
proteases [33], changes to this residue are likely to have
the greatest effect on speci¢city of our inhibitor for a given
target. A complete scanning library consisting of 18 natural
amino acids and the isosteric methionine analog norleucine
was constructed. This library of inhibitors was used to
create pro¢les of inhibitor speci¢city for proteases targeted
by DCG-04 and MB-074 (Figure 6).
Competition analysis was used to determine the potency of
each member of the P2 scanning library towards multiple
protease targets. Lysates from DC2.4 cells were preincu-
bated with 50 WM of each of the 19 DCG library members
and residual activity measured for multiple proteases using
125I-DCG-04 (Figure 6A). In general, residues containing
non-charged aliphatic side chains [isoleucine (I), leucine
(L; DCG-04) and norleucine (n)] show the highest activity
and the lowest amount of speci¢city across the pro¢le of
polypeptides. More interesting was the apparent selectivity
of several DCG family compounds for a subset of labeled
polypeptides. For example, the valine containing com-
pound competed for polypeptides 1, 2 and cathepsin B
but had little effect on the remaining species. In contrast,
both the phenylalanine and tyrosine containing compounds
showed speci¢city for polypeptides 2, 3, 4 and 5. Further-
more, while the aspartic acid and glycine containing com-
pounds showed relatively poor activity overall, they
showed some degree of speci¢city against polypeptide 2.
Using these data to simultaneously score inhibitors for po-
tency and selectivity will be valuable for the development
of speci¢c inhibitors.
Similar competition experiments were performed with the
library of DCG analogs to obtain pro¢les of single pro-
teases. DC2.4 lysates were preincubated with P2 library
and then labeled with the cathepsin B-speci¢c compound
125I-MB-074 (Figure 6B). This method allowed analysis of
cathepsin B speci¢city in crude extracts. As found in the
125I-DCG-04 labeling (Figure 6B), isoleucine, leucine, va-
line and norleucine analogs showed the highest activity
followed by the aromatic amino acids (W, Y, F) containing
compounds. In order to explore speci¢city pro¢les for addi-
tional cysteine proteases that could not be speci¢cally la-
beled in crude extracts, we performed the same competi-
tion labeling experiment described above using a puri¢ed
enzyme. Preincubation of puri¢ed cathepsin H with the
library of compounds followed by 125I-DCG-04 labeling
resulted in a speci¢city pro¢le that was remarkably similar
to the pro¢le observed for cathepsin B in crude extracts
(Figure 6C). While these two proteases are quite different
in their biological functions, it is clear from these data that
the two have similar inhibitor speci¢city in the S2 pocket.
Since it is unlikely that two distinct proteases will exhibit
identical reactivity across a diverse set of inhibitors, it may
be possible to use this information from inhibitor libraries
to generate ‘speci¢city ¢ngerprints’ for a series of well-
characterized proteases. Establishment of a database of
protease inhibitor pro¢les could potentially be used to es-
tablish target identi¢cation by labeling of crude protein
mixtures in the presence of compound libraries. Further-
more, extension of this methodology to longer, more di-
verse peptide substrate analogs may further accentuate the
speci¢city differences of closely related protease species.
Pro¢ling across tissue types
Having determined that both DCG-03 and DCG-04 were
capable of covalently modifying multiple papain family
Figure 7. Activity pro¢ling of cysteine proteases across tissue
types. Labeling of total cellular extracts (100 Wg protein/lane) from
rat brain, kidney, liver, prostate and testis with 125I-DCG-04 at pH
5.5. Samples were analyzed by SDS^PAGE followed by
autoradiography. A pre-heating control was included for each
tissue type to indicated background labeling.
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proteases in extracts generated from several cell lines, we
wanted to test the utility of these reagents for pro¢ling
protease activity patterns in various tissues. In this way, a
crude map of protease activities can be created for each
tissue and ultimately the identity of these major species
can be determined by virtue of their reactivity towards the
DCG-04 af¢nity probe.
Samples of rat brain, kidney, liver, prostate and testis tissue
were used to make crude homogenates at the reduced pH
of the lysosome (pH 5.5). Samples were labeled with 125I-
DCG-04 and analyzed by SDS^PAGE/autoradiography
(Figure 7). The most intense labeling in the 20^30 kDa
size range was observed for kidney and liver tissue, con-
sistent with the known protein processing functions of
these organs. Comparison of the labeling pro¢les across
tissue samples indicated that while some of the modi¢ed
polypeptides were observed in multiple tissues at nearly
identical intensities, several polypeptides showed in-
creased or speci¢c activity in a given tissue type. These
data are consistent with the ¢ndings that cathepsin expres-
sion patterns and activities are differentially regulated
across tissue types [48]. In addition, the major species la-
beled by 125I-DCG-04 were in the 20^30 kDa size range
and are likely to be lysosomal cathepsins such cathepsins
B, H and L. To con¢rm this hypothesis, we chose rat
kidney as a starting material for the af¢nity puri¢cation
of targeted cysteine protease using DCG-04 as an af¢nity
tag. The results of this puri¢cation are described below.
Identi¢cation of DCG-04-modi¢ed proteins in rat kidney by
af¢nity chromatography
Perhaps the greatest attribute of a functional proteomics
tool is its ability to aid in the identi¢cation of targeted
proteins. As shown above, rat kidney contains several poly-
peptides that were ef¢ciently targeted by DCG-04 (Figure
7). Three prominently labeled species of 23 kDa, 28 kDa
and 30 kDa were identi¢ed in total kidney extract (Figure
8A). When subjected to anion exchange chromatography,
these polypeptides partitioned over a wide range of the
elution gradient as determined by DCG-04 labeling of col-
umn fractions (Figure 8B). Two pools of fractions were
Figure 8. Af¢nity puri¢cation of DCG-04-targeted proteases from rat kidney. (A) Labeling of total cellular extracts (100 Wg protein/lane) from
rat kidney with 50 WM DCG-04 at pH 5.5. Samples were analyzed by SDS^PAGE followed by af¢nity blot. (B) Anion exchange
chromatography of rat kidney lysate using a gradient from 0.05 to 1 M NaCl, pH 9.0. Fractions were analyzed by addition of DCG-04 (50
WM) followed by SDS^PAGE and af¢nity blotting. Fractions containing DCG-04-labeled proteins were pooled (fractions 5^7 and fractions
11^13). (C) Pooled fractions were labeled with DCG-04 (50 WM), and DCG-04-modi¢ed proteins bound to a monomeric avidin column,
washed with 1 M NaCl, and eluted using 2 mM biotin. A sample of material from pools prior to application to the af¢nity column (PC) along
with column £ow through (FT) and biotin elution fractions (E1^E5) were analyzed by SDS^PAGE followed by silver staining. (D) Elutions
containing labeled proteins were pooled, volumes reduced and analyzed by 2D IEF electrophoresis followed by silver staining. Spots
labeled with numbers were excised and used for sequencing.
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chosen based on differences in labeled protein composi-
tion. Fractions 7^9 contained predominantly the 23 and 28
kDa species, and fractions 11^13 contained the 23, 28 and
30 kDa species. Modi¢ed proteins were af¢nity-puri¢ed
using a monomeric avidin column that has a reduced bind-
ing af¢nity for biotin and thus the bound proteins could be
competitively eluted with high concentrations of biotin (2
mM). The af¢nity column puri¢ed all DCG-04-modi¢ed
polypeptides in both pools as visualized by SDS^PAGE
and silver staining of eluted fractions (Figure 8C). To fur-
ther resolve DCG-04-modi¢ed polypeptides, peak fractions
were concentrated, separated by 2D SDS^PAGE and visu-
alized by silver staining (Figure 8D).
The 30 kDa polypeptide (cat B) yielded a single spot near
the acidic end of the gel, while the 28 kDa polypeptide
(spot #1) resolved into a streak near the basic end of the
gel. The 23 kDa band yielded three distinct spots ranging
in pI from acidic to basic (spots #2^5). All spots were
excised from the gel and subjected to in-gel trypsin diges-
tion, followed by peptide extraction and analysis by mass
spectrometry. The protein amount in the 30 kDa spot was
not suf¢cient for unambiguous identi¢cation based on MS
data alone. Thus its identity was con¢rmed as cathepsin B
by labeling of anion exchange column fractions with the
cathepsin B-speci¢c label 125I-MB-074 [23] (data not
shown).
The tryptic mass ¢ngerprint obtained for the 28 kDa band
as well as two of the three 23 kDa spots (#2, #3) indicated
the presence of cathepsin H. Furthermore, all three digests
contained a MH 1429.7 peptide that was sequenced by
low energy dissociation analysis (CID; Figure 9). The re-
sulting sequence, MGEDSYPYL/IGK, unequivocally
matched cathepsin H. The amino-terminus of cathepsin
H is heterogeneous, explaining the presence of multiple
cathepsin H isoforms at similar molecular weights [49]. In
addition, cathepsin H exists as both single chain and two-
chain isoforms differing by about 5 kDa [49]. Thus, spot #1
is likely to be the single chain form of cat H while spots #2
and #3 may represent heavy chain versions of the two-
chain isoform.
The remaining 23 kDa spots (#4, #5) did not yield se-
quence data; however, spot #5 was identi¢ed as cathepsin
L based on the tryptic peptides observed in its digest, its
size and pI. Thus, DCG-04 successfully identi¢ed the pre-
dominant active cysteine proteases in rat kidney as cathep-
sins B, H and L in agreement with previous studies [48].
Signi¢cance
Functional proteomics methods are becoming more impor-
tant as genomics efforts complete the sequences of various
organisms. Cravatt and co-workers have established the
utility of a functional proteomics tool speci¢c for the serine
hydrolase family of proteases [32]. We show here that a
general af¢nity label, DCG-04, and its radiolabeled coun-
terpart, 125I-DCG-04, can be used to pro¢le cysteine pro-
tease activities in crude extracts from cells and tissues, as
well as throughout multiple stages of a physiological pro-
cess. Diversi¢cation of the peptide portion of the inhibitor
using solid-phase synthesis established the utility of small
libraries of compounds for determining pro¢les of inhibitor
speci¢city for both characterized and potentially novel en-
zymes. The information obtained from these libraries pro-
vides a starting point for the development of protease-spe-
Figure 9. Low energy CID spectrum of tryptic peptides with MH = 1429.7. The doubly charged ion at m/z 715.35 was selected as a
precursor ion. Only the C-terminal fragment ions used for sequence determination are labeled.
CHBIOL 13 11-8-00
578 Chemistry & Biology 2000, Vol 7 No 8
ci¢c inhibitors and also provides functional information
about a protease target that may serve as a method for
rapid identi¢cation of targets in crude protein mixtures.
Furthermore, DCG-04 can be used as an af¢nity puri¢ca-
tion reagent to aid in the identi¢cation of proteases se-
lected by virtue of their reactivity towards our electrophilic
probes. Target identi¢cation of proteases from crude ex-
tracts based on activity pro¢les will assist in the assignment
of protein function as well as potentially identify new play-
ers in processes such as carcinogenesis. Finally, further
diversi¢cation of these reagents is likely to extend their
utility for the study of additional physiological processes
that are regulated by proteolysis.
Materials and methods
Synthesis of DCG-04, DCG-03 and P2 diverse library
Solution-phase synthesis of ethyl (2S,3S)-oxirane-2,3-dicar-
boxylate. The synthesis of this compound has been reported else-
where [23].
Solid-phase synthesis of DCG-04 and DCG-03. The details of the
solid-phase synthesis are shown in Figure 2. All resins and reagents
were purchased from Advanced Chemtech (Louisville, KY, USA). Dry
Fmoc-Rink amide resin (0.7 mmol/g) was weighed into 1U10 cm col-
umns (Waters). The columns were ¢tted with Te£on stopcocks and
connected to a 20 port vacuum manifold (Waters) that was used to drain
solvents and reagents from the columns. The resin was swelled using
DMF. The Fmoc protecting group was removed (deprotected) by treat-
ment with a 20% piperidine solution in DMF for 15 min. The resin was
washed with 3U3 ml of DMF and 3U3 ml of CH2Cl2.
Fmoc-Lys(biotin)-OH (100 mg, 70 Wmol, 1 eq), DIC (11.4 Wl, 112 Wmol,
1.5 eq), HOBT (15.1 mg, 112 Wmol, 1.5 eq) were dissolved in 2 ml of
DMF, added to the resin and the reaction was agitated for 1 h. The resin
was washed, and the N-terminal Fmoc group was deprotected. Fmoc-6-
aminohexanoic acid (74.2 mg, 210 Wmol, 3 eq), DIC (21.4 Wl, 210 Wmol,
3 eq) and HOBT (28.4 mg, 210 Wmol, 3 eq) were dissolved in 2 ml DMF,
and agitated with the resin for 1 h, followed by washing and deprotection
of the N-terminal Fmoc group (synthesis of DCG-03 leaves this step
out). Fmoc-Tyr(But)-OH (160.8 mg, 350 Wmol, 5 eq), DIC (35.6 Wl, 350
Wmol, 5 eq) and HOBT (47.2 mg, 350 Wmol, 5 eq) were dissolved in 2 ml
DMF, and the reaction agitated for 1 h followed by washing and
N-terminal Fmoc group deprotection. Fmoc-leucine (61.8 mg, 350
Wmol, 5 eq), DIC (35.6 Wl, 350 Wmol, 5 eq) and HOBT (47.2 mg, 350
Wmol, 5 eq) were dissolved in 2 ml DMF, and the reaction agitated for
1 h. The resin was washed followed by deprotection of the N-terminal
Fmoc group. Ethyl (2S,3S)-oxirane-2,3-dicarboxylate (22.4 mg, 140
Wmol, 2 eq), DIC (14.2 Wl, 140 Wmol, 2 eq) and HOBT (18.9 mg,
140 Wmol, 2 eq) were dissolved in 2 ml DMF, and the reaction agitated
for 1 h. The resin was washed with 3U3 ml of DMF and 3U3 ml of
CH2Cl2.
The inhibitors were cleaved from the resin using 1 ml of cleavage cock-
tail (95% TFA, 2.5% water, 2.5% triisopropylsilane). The mix was col-
lected, and the resin washed with 0.5 ml of fresh cleavage cocktail. Ice
cold ether (15 ml) was used to precipitate the product. The solid was
collected and dissolved in a minimal amount of DMSO. The product was
puri¢ed on a C18 reverse phase high performance liquid chromatogra-
phy (HPLC) column (Waters, Delta-Pak) using a linear gradient of 0^
100% water^acetonitrile. Fractions containing the product were pooled,
frozen and lyophilized to dryness. The identity of the product was
con¢rmed by mass spectrometry. Electrospray mass spectrum: [M+H]
calculated for DCG-03 C37H55N7O10S 791.0, found 791.0; calculated for
DCG-04 C43H66N8O11S 903.1, found 903.7.
A similar protocol was used to synthesize the P2 diverse library except
that synthesis was performed using a 96 well manifold (Robbins Scien-
ti¢c). Synthesis was carried out on 20 mg of Rink resin per well, and all
coupling conditions were identical to those described above. Each of 18
natural amino acids (except cysteine and methionine) and including
norleucine were coupled after addition of the amino hexanoic acid
spacer group. All subsequent steps were performed as described above
except peptides were used without HPLC puri¢cation due to the fact that
products were found to be pure by HPLC analysis. Identity of products
was con¢rmed by mass spectrometry. Electrospray mass spectrum:
X = Ala calculated [M+H] for C40H60N8O11S 862.0, found 861.9; Arg
C42H66N12O11S 946.5, found 946.7; Asn C41H61N9O12S 905.0, found
904.9; Asp C41H60N8O13S 906.0, found 905.9; Glu C42H62N8O13S
920.0, found 919.8; Gln C42H63N9O12S 919.0, found 918.9; Gly
C39H58N8O11S 848.0, found 847.7; His C43H62N10O11S 928.0, found
927.7; Ile C43H66N8O11S 904.1, found 904.0; Leu C43H66N8O11S
904.1, found 904.0; Lys C43H67N9O11S 919.0, found 919.0;
C46H64N8O11S 938.0, found 937.8; Pro C42H62N8O11S 888.0, found
877.8; Ser C40H60N8O12S 878.0, found 877.8; Thr C41H62N8O12S
892.0, found 892.0; Trp C48H65N9O11S 977.1, found 976.7; Tyr
C46H64N8O12S 954.1, found 953.8; Val C42H64N8O11S 890.0, found
890.0; Nle C43H66N8O11S 904.1, found 903.9.
Radiolabeling of inhibitors
All compounds were iodinated and isolated using the previously re-
ported protocol [23].
Preparation of cell and tissue lysates
Tissues were Dounce-homogenized in buffer A (50 mM Tris pH 5.5,
1 mM dithiothreitol (DTT), 5 mM MgCl2, 250 mM sucrose) and extracts
centrifuged at 1100Ug for 10 min at 4³C. The resulting supernatant was
centrifuged at 22 000Ug for 30 min at 4³C and ¢nal supernatants used
for all labeling experiments. Cells were lysed using glass beads (6 104
Wm) in buffer A and supernatants centrifuged at 15 000Ug for 15 min at
4³C. The total protein concentration of the ¢nal supernatants (soluble)
was determined by BCA protein quanti¢cation (Pierce).
Labeling of lysates with 125I-DCG-04, 125I-DCG-03 and
125I-MB-074
Equivalent amounts of radioactive inhibitor stock solutions (approxi-
mately 106 cpm per sample) were used for all labeling experiments.
Samples of lysates (100 Wg total protein in 100 Wl buffer; 50 mM Tris
pH 5.5, 5 mM MgCl2, 2 mM DTT) were labeled for 1 h at 25³C unless
noted otherwise. Samples were quenched by dilution of 4USDS sample
buffer to 1U (for one-dimensional (1D) SDS^PAGE) or by dissolving
urea to a ¢nal concentration of 9.5 M (for 2D SDS^PAGE).
Gel electrophoresis
1D SDS^PAGE, 2D IEF gels were performed as described [22].
SDS^PAGE^Western blotting detection of and autoradiography
of DCG-04-modi¢ed proteins
Quenched DCG-04-labeled samples were separated by SDS^PAGE
(100 Wg/lane) and transferred to nitrocellulose using a semi-dry appara-
tus. Membranes were blocked using phosphate-buffered saline (PBS)
and 5% (w/v) dry milk for 30 min at 25³C. Blots were washed brie£y with
PBS/0.2% Tween (PBS^Tween) and treated with avidin-horseradish
peroxidase conjugate (VectaStain) in PBS^Tween for 30 min at 25³C.
Blots were washed three times with PBS^Tween, treated with ECL
reagents (Amersham) and exposed to ¢lm.
Competition labeling experiments
Lysates from the dendritic cell line DC2.4 were prepared at pH 5.5 as
described above. Puri¢ed cathepsin H was purchased from Calbiochem
(San Diego, CA, USA). Samples of lysates (100 Wg total protein in 100
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Wl buffer B; 50 mM Tris pH 5.5, 5 mM MgCl2, 2 mM DTT) or puri¢ed
cathepsin H (1 Wg protein in 100 Wl buffer A) were preincubated with 50
WM of each library member (diluted from 5 mM DMSO stocks) for 2 h at
room temperature. Samples were then labeled by addition of either 125I-
DCG-04 or 125I-MB-074 to each sample followed by further incubation at
room temperature for 1 h. Samples were quenched by the addition of
4Usample buffer to 1U followed by boiling for 5 min. Samples were
analyzed by SDS^PAGE followed by autoradiography.
Preparation of mouse carcinoma cell lines
Mouse melanoma cell lines were prepared by a single topical applica-
tion of 25 Wg of the chemical mutagen dimethylbenzanthracene to the
skin of mice followed by biweekly application of 100 WM of the tumor
promoter, TPA, over an extended period of time essentially as described
[50^52].
Protein identi¢cation of DCG-04-modi¢ed proteins
A soluble fraction of rat kidney lysate (80 mg total protein) was diluted
into anion exchange starting buffer (50 mM Tris, 50 mM NaCl, pH 9.0).
The lysate was applied to a HitrapQ anion exchange column (Amer-
sham Pharmacia Biotech) and eluted using a linear gradient of 0.05^1
M NaCl, pH 9. An aliquot from each fraction (50 Wl) was incubated with
50 WM DCG-04 at 25³C for 1 h and analyzed on a 12.5% SDS^PAGE
gel followed by af¢nity blotting as described above.
The fractions containing peak labeling of the 25^30 kDa bands were
pooled, and DCG-04 was added to a ¢nal concentration of 50 WM. Pools
were incubated at 25³C for 2 h and then 12 h at 4³C. Unbound inhibitor
was removed and buffer was exchanged with PBS using a PD-10 col-
umn (Pharmacia). Samples were applied to a monomeric avidin column
(1 ml bed volume; Pierce), and the column was washed with 6U1 ml
fractions of 1 M NaCl. Bound proteins were eluted with 0.5 ml fractions
of 2 mM biotin/100 mM NH4HCO3 buffer. All wash and eluent fractions
were analyzed by SDS^PAGE and silver staining. The fractions contain-
ing the labeled 25^30 kDa bands were pooled, the volume reduced by
lyophilization and solid urea added to 9.5 M along with BME to 5%, NP-
40 to 2%, pH 5^7 ampholytes to 1.6% and pH 3.5^10 ampholytes to
0.4%. Samples were applied to IEF tube gels and electrophoresed at
1000 V for 13 h followed by separation in the second dimension on
12.5% SDS^PAGE gels.
The resulting gels were ¢xed in 12% acetic acid/50% methanol stained
with silver according to reported protocols [22]. Spots were excised,
digested with trypsin and the peptide molecular weight measurements
were carried out by matrix-assisted laser desorption ionization-mass
spectrometry (PE Voyager DESTR). Sequence determination was per-
formed on a quadrupole time-of-£ight hybrid tandem mass spectrometer
(PE QSTAR) equipped with a Protome nanospray source. This instru-
ment affords high resolution and accuracy for mass measurement and
the CID data obtained allowed unambiguous sequence determination.
Database searches were performed using the Protein Prospector soft-
ware package (http://prospector.ucsf.edu/).
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